Please login to the form below

Not currently logged in
Email:
Password:

insulin aspart

This page shows the latest insulin aspart news and features for those working in and with pharma, biotech and healthcare.

Novo follows Sanofi, Lilly with insulin price cut in US

Novo follows Sanofi, Lilly with insulin price cut in US

The Danish drugmaker says it will offer an authorised generic version of NovoLog (insulin aspart) at around $145 per vial, roughly half the branded drug’s current US list price, from ... which offered a 50% cheaper version of its Humalog (insulin lispro

Latest news

  • Novo Nordisk preps for speedy oral GLP-1 drug filing Novo Nordisk preps for speedy oral GLP-1 drug filing

    10% gain for Tresiba (insulin degludec) and a sharp increase for Xultophy, a combination insulin/GLP-1 shot which more than doubled to 1.6bn krone. ... Novo’s CEO Lars Fruergaard Jørgensen. New fast-acting mealtime insulin Fiasp (insulin aspart),

  • Gilead's hepatitis B virus treatment set for European approval Gilead's hepatitis B virus treatment set for European approval

    The dual-therapy works to reduce high blood glucose while enhancing glucose-dependent insulin secretion and reducing glucagon release. ... Meanwhile, Novo Nordisk looks set to add Fiasp (insulin aspart) to its diabetes drug stable, as the fast-acting

  • Novo Nordisk's Tresiba gaining ground in basal insulin market Novo Nordisk's Tresiba gaining ground in basal insulin market

    Sales of Novo Nordisk's new basal insulin product Tresiba have started to gather momentum since its US launch in January, rising three-fold in the first half of the year. ... Nevertheless, the strong sales performance for Tresiba and other new insulin

  • Tresiba safer than insulin glargine, says Novo Nordisk Tresiba safer than insulin glargine, says Novo Nordisk

    Moreover, it could also differentiate Tresiba from biosimilar copies of Sanofi's drug that are starting to reach the market and threaten to disrupt the basal insulin category. ... Last October however the Danish drugmaker finally won US approval for

  • Novo Nordisk finally bags insulin degludec approval in US Novo Nordisk finally bags insulin degludec approval in US

    Long-acting basal insulin Tresiba (insulin degludec) and combination drug Ryzodeg (insulin degludec and insulin aspart) will now be able to compete head-to-head in the market with Sanofi's ... that the drug – along with Ryzodeg and Xultophy (insulin

More from news
Approximately 2 fully matching, plus 21 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Page & Page

Page & Page is a new kind of marketing communications consultancy. We change beliefs and behaviours to improve health outcomes...

Latest intelligence

Five key trends in precision and personalised healthcare
Here, we deep dive into five of the key trends in precision medicine and personalised healthcare to explore how the healthcare industry is changing and how pharmaceutical and biotech companies...
OPEN Health Graduate Programme: from OPEN VIE to OPEN Health Medical Communications
Isobel Owens shares her experience of the OPEN Health Graduate Programme from OPEN VIE to OPEN Health Medical Communications...
Language barriers: Obesity has become a loaded word
...

Infographics